drugset / Trial / NCT02667639
Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this first in human study is to evaluate the safety and tolerability of RPH-104 in humans.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Goflikicept | Monoclonal antibody | 4 mg | Subcutaneous |
| Comparator | Goflikicept | Monoclonal antibody | 20 mg | Subcutaneous |
| Comparator | Goflikicept | Monoclonal antibody | 40 mg | Subcutaneous |
| Comparator | Goflikicept | Monoclonal antibody | 80 mg | Subcutaneous |
| Comparator | Goflikicept | Monoclonal antibody | 160 mg | Subcutaneous |
Indications
No indication recorded.